Nota: La página que ha solicitado no está en su idioma predeterminado. Usted está usando nuestra plataforma en otro idioma ahora.

Reduction in U.S. direct spending on originator biologics as of 2018

Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2018

Region

United States

Survey time period

as of 2018

Supplementary notes

CBO = Congressional Budget Office;
RAND = RAND Corporation;
QI = QuintilesIMS (IQVIA);
ESI = Express Scripts Inc.
* Actually, the RAND gives a range of 40-93 billion U.S. dollars.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Generics and biosimilars "

Other statistics that may interest you Generics and biosimilars

Global overview

4

Top companies

4

U.S. market

6

Patent expiration

6

Savings

7

Biosimilars

7

Further related statistics

19
Statista Accounts: Access All Statistics. Starting from $2,388 USD / Year
Learn more about how Statista can support your business.